Cargando…
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response
BACKGROUND: One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports. METHODS: A retrospective datab...
Autores principales: | Libertini, M., Mitra, I., van der Graaf, W. T. A., Miah, A. B., Judson, I., Jones, R. L., Thomas, K., Moskovic, E., Szucs, Z., Benson, C., Messiou, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950191/ https://www.ncbi.nlm.nih.gov/pubmed/29785261 http://dx.doi.org/10.1186/s13569-018-0100-3 |
Ejemplares similares
-
Pazopanib, a promising option for the treatment of aggressive fibromatosis
por: Szucs, Zoltan, et al.
Publicado: (2017) -
Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
por: Martin-Liberal, Juan, et al.
Publicado: (2013) -
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010) -
An Aggressive Retroperitoneal Fibromatosis
por: Campara, Zoran, et al.
Publicado: (2016) -
Management of aggressive fibromatosis
por: Zhang, Zhijun, et al.
Publicado: (2021)